PDCD1 and non-small cell lung carcinoma: In the past few years, preoperative programmed cell death protein 1 (PD-1) or its ligand, PD-L1, alone or combined chemotherapy, has been investigated in several clinical trials of non-small cell lung cancer (NSCLC) (3–7).